AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20397964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem (Edluar) 10 mg
Number of subjects: 70
Study 20397964 — intervention group
Group type: COMPARATOR
Intervention: Oral zolpidem (Ambien) 10 mg
Number of subjects: 70
Study 20397964 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 70
Study 18415895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux®)
Number of subjects: 0
Study 18415895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®)
Number of subjects: 0
Study 18415895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cytotoxic agents with monoclonal antibodies
Number of subjects: 0
Study 15976585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (continuous wear)
Number of subjects: 45
Study 15976585 — intervention group
Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (daily wear)
Number of subjects: 45
Study 15976585 — intervention group
Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (continuous wear)
Number of subjects: 45
Study 15976585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (daily wear)
Number of subjects: 45
Study 15041080 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 38
Study 15041080 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM and cisplatin
Number of subjects: 38
Study 15041080 — intervention group
Group type: COMPARATOR
Intervention: No cisplatin (BVM)
Number of subjects: 38
Study 11578917 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical gastrectomy and regional lymphadenectomy (Japan)
Number of subjects: 0
Study 11578917 — intervention group
Group type: COMPARATOR
Intervention: Standard gastrectomy (West)
Number of subjects: 0
Study 11578917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant and neoadjuvant treatment regimens (Japan and West)
Number of subjects: 0
Study 9258576 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone therapy (oral administration during the second luteal phase)
Number of subjects: 6
Study 9258576 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (3% saline solution administered on an early follicular and a late luteal phase day)
Number of subjects: 6
Study 9258576 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase (control phase for each subject)
Number of subjects: 6
Study 8298782 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm splints (postoperative period)
Number of subjects: 46
Study 8298782 — intervention group
Group type: COMPARATOR
Intervention: No arm splints (postoperative period)
Number of subjects: 46
Study 3638441 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based health behavior change intervention, 12 weekly sessions and six maintenance sessions over nine months.
Number of subjects: 0
Study 3638441 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 0
Study 31595955 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth measures (standardized weight, length/height, body mass index) during ages 6.5-11.5 years
Number of subjects: 0
Study 31595955 — intervention group
Group type: COMPARATOR
Intervention: Growth measures during gestation and the first year of life
Number of subjects: 0
Study 30031383 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost camp intervention (14 lessons over 2 days, followed by Booster sessions)
Number of subjects: 300
Study 30031383 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 300
Study 27051376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils fiberoptic scope
Number of subjects: 60
Study 27051376 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 24754044 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise immediately before sexual activity (3×/week)
Number of subjects: 52
Study 24754044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sexual activity (3×/week)
Number of subjects: 52
Study 24754044 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3×/week)
Number of subjects: 52
Study 24754044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sexual activity and exercise
Number of subjects: 52
Study 22551813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 36
Study 22551813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20463094 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets/week increase in l-T(4)
Number of subjects: 60
Study 20463094 — intervention group
Group type: EXPERIMENTAL
Intervention: Three tablets/week increase in l-T(4)
Number of subjects: 60
Study 20463094 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring TSH every 4 weeks
Number of subjects: 60
Study 20463094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimester-specific TSH lower reference range of 0.1 mIU/liter
Number of subjects: 60
Study 18166547 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 2 mg/day
Number of subjects: 345
Study 18166547 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 3 mg/day
Number of subjects: 345
Study 18166547 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release 4 mg/day
Number of subjects: 345
Study 18166547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 18166547 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (all doses)
Number of subjects: 345
Study 15923670 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b (100 mug weekly) combined with daily lamivudine (100 mg)
Number of subjects: 266
Study 15923670 — intervention group
Group type: COMPARATOR
Intervention: Peg-interferon alpha-2b (100 mug weekly) combined with placebo
Number of subjects: 266
Study 15923670 — intervention group
Group type: EXPERIMENTAL
Intervention: Host induced flare
Number of subjects: 266
Study 15923670 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus induced flare
Number of subjects: 266
Study 12952117 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 2 sprays per nostril, twice daily
Number of subjects: 428
Study 12952117 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray plus loratadine 10 mg daily
Number of subjects: 428
Study 12952117 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily plus placebo nasal spray
Number of subjects: 428
Study 12952117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) nasal spray
Number of subjects: 428
Study 10632736 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin after aspirin treatment
Number of subjects: 0
Study 10632736 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin after placebo treatment
Number of subjects: 0
Study 10632736 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 0
Study 10632736 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 10632736 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of desmopressin
Number of subjects: 0
Study 10632736 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of desmopressin
Number of subjects: 0
Study 8649552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine with estrogen replacement therapy (ERT)
Number of subjects: 318
Study 8649552 — intervention group
Group type: COMPARATOR
Intervention: Tacrine without estrogen replacement therapy (ERT)
Number of subjects: 318
Study 8649552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 1622163 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Number of subjects: 163
Study 1622163 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Number of subjects: 163
Study 6085099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic povidone-iodine ('Betadine') alone
Number of subjects: 45
Study 6085099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic povidone-iodine ('Betadine') covered with an incise drape ('Steri-Drape')
Number of subjects: 45
Study 6085099 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing incise drape ('Ioban') alone
Number of subjects: 45
Study 6085099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 30924513 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor and delivery education program
Number of subjects: 151
Study 30924513 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing guidance
Number of subjects: 151
Study 28727629 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated inpatient split-dose bowel preparation system
Number of subjects: 969
Study 26505139 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback
Number of subjects: 44
Study 26505139 — intervention group
Group type: COMPARATOR
Intervention: No-feedback control
Number of subjects: 44
Study 25439694 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg intravenously, six injections, one every 4 weeks)
Number of subjects: 921
Study 25439694 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 921
Study 25439694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 22527350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methantheline (100 mg) as immediate-release coated tablets (IR)
Number of subjects: 12
Study 22527350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methantheline (100 mg) in watery solution (SOL)
Number of subjects: 12
Study 22527350 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1.0 mg)
Number of subjects: 12
Study 22527350 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 12
Study 21309495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil (group R)
Number of subjects: 96
Study 21309495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg remifentanil with venous retention for 30 s (group R')
Number of subjects: 96
Study 21309495 — intervention group
Group type: COMPARATOR
Intervention: 2 ml saline (placebo group)
Number of subjects: 96
Study 17698746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (SD <= 2)
Number of subjects: 408
Study 17698746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (SD > 2)
Number of subjects: 408
Study 16243997 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 microg/kg oral)
Number of subjects: 30
Study 16243997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12199431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin hydrochloride (220 ppm in feed from day 71 to day 91)
Number of subjects: 61
Study 12199431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against Mycoplasma hyopneumoniae (at four and 28 days of age)
Number of subjects: 61
Study 12199431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lincomycin hydrochloride and vaccination
Number of subjects: 61
Study 12199431 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 61
Study 10420905 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (10, 20, or 40 ng/kg/min)
Number of subjects: 130
Study 10420905 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (20 ng/kg/min)
Number of subjects: 130
Study 10420905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 7776458 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human tumor necrosis factor (200, 400, and 1,000 micrograms) given intravesically weekly for 11 weeks (dwell time 2 hours)
Number of subjects: 9
Study 2186066 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) alone
Number of subjects: 66
Study 2186066 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR plus cognitive therapy (PMR + Cog)
Number of subjects: 66
Study 2186066 — intervention group
Group type: COMPARATOR
Intervention: Pseudomeditation (placebo control)
Number of subjects: 66
Study 2186066 — intervention group
Group type: COMPARATOR
Intervention: Continued headache monitoring (control)
Number of subjects: 66
Study 2186066 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR and PMR + Cog (combined)
Number of subjects: 66
Study 2186066 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR + Cog
Number of subjects: 66
Study 2186066 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 66
Study 378986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in combination with a thiazide diuretic
Number of subjects: 27
Study 378986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in combination with a low sodium diet
Number of subjects: 27
Study 378986 — intervention group
Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 27
Study 30653416 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 10
Study 30653416 — intervention group
Group type: COMPARATOR
Intervention: Sham (mock IPC)
Number of subjects: 10
Study 30653416 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study 28185444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-palmitoleic acid (720 mg/day for 8 weeks)
Number of subjects: 20
Study 28185444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25928427 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention (n = 17)
Number of subjects: 30
Study 25928427 — intervention group
Group type: COMPARATOR
Intervention: Control condition (assessment-only, n = 13)
Number of subjects: 30
Study 24115080 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 97
Study 24115080 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 97
Study 21871373 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 2.5 mg)
Number of subjects: 40
Study 21871373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean dose 3 mg)
Number of subjects: 40
Study 19421075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day diary
Number of subjects: 0
Study 19421075 — intervention group
Group type: COMPARATOR
Intervention: 7-day diary
Number of subjects: 0
Study 17362248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 20
Study 17362248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15226521 — intervention group
Group type: EXPERIMENTAL
Intervention: Held by a parent (HLD)
Number of subjects: 106
Study 15226521 — intervention group
Group type: COMPARATOR
Intervention: Supine position (SUP)
Number of subjects: 106
Study 15226521 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month-old infants
Number of subjects: 106
Study 11561920 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam injection prior to study
Number of subjects: 0
Study 11561920 — intervention group
Group type: COMPARATOR
Intervention: Control (no midazolam injection)
Number of subjects: 0
Study 10802404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day tibolone
Number of subjects: 94
Study 10802404 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone
Number of subjects: 94
Study 10802404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 8921820 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (10-100 micrograms)
Number of subjects: 19
Study 8921820 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (10-25 micrograms)
Number of subjects: 19
Study 1653141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan (20 mg plus 20 mg)
Number of subjects: 74
Study 1653141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6811034 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 0
Study 6811034 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte homogenates from flushers
Number of subjects: 0
Study 6811034 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte homogenates from non-flushers
Number of subjects: 0
Study 30511312 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic percutaneous inguinal ring suturing (PIRS)
Number of subjects: 32
Study 30511312 — intervention group
Group type: COMPARATOR
Intervention: Open modified Marcy technique
Number of subjects: 32
Study 29519502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg NGM282
Number of subjects: 82
Study 29519502 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg NGM282
Number of subjects: 82
Study 29519502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 29519502 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 (both doses combined)
Number of subjects: 82
Study 27395805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ERP-based treatment (1 session psychoeducation, 2 sessions ERP plus e-therapy maintenance)
Number of subjects: 10
Study 27395805 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment
Number of subjects: 10
Study 27395805 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up
Number of subjects: 10
Study 24955448 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 184
Study 24955448 — intervention group
Group type: COMPARATOR
Intervention: 14-day sequential therapy
Number of subjects: 184
Study 21659900 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + diet (n = 5)
Number of subjects: 9
Study 21659900 — intervention group
Group type: COMPARATOR
Intervention: diet (n = 4)
Number of subjects: 9
Study 20189560 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 52
Study 20189560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17611252 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 degrees back-up position
Number of subjects: 40
Study 17611252 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study 17611252 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of positions
Number of subjects: 40
Study 16286463 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot chill
Number of subjects: 180
Study 16286463 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 180
Study 12040992 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions in ultrasound pressure application (Group 1)
Number of subjects: 65
Study 12040992 — intervention group
Group type: COMPARATOR
Intervention: No instructions in ultrasound pressure application (Group 2)
Number of subjects: 65
Study 10768024 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic response Arabic letter distance visual acuity test chart
Number of subjects: 0
Study 7593442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.1 mg
Number of subjects: 12
Study 7593442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.05 mg
Number of subjects: 12
Study 7593442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST) 0.01 mg
Number of subjects: 12
Study 7593442 — intervention group
Group type: COMPARATOR
Intervention: Control saline injection
Number of subjects: 12
Study 7593442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting somatostatin analog (ST)
Number of subjects: 12
Study 2367197 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees elevated position
Number of subjects: 64
Study 2367197 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees elevated position
Number of subjects: 64
Study 2367197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair position
Number of subjects: 64
Study 2367197 — intervention group
Group type: COMPARATOR
Intervention: Flat bed position
Number of subjects: 64
Study 2367197 — intervention group
Group type: COMPARATOR
Intervention: Sidelying position
Number of subjects: 64
Study 30281074 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial catheter lock solution containing trimethoprim 5 mg/mL, ethanol 25%, and Ca‐EDTA 3% (IMD)
Number of subjects: 270
Study 30281074 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/mL (active control heparin, ACH)
Number of subjects: 270
Study 30281074 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial catheter lock solution (IMD)
Number of subjects: 270
Study 30281074 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/mL (ACH)
Number of subjects: 270
Study 29624592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine CVD 103-HgR (5 × 10^8 CFU)
Number of subjects: 46
Study 27053641 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PES
Number of subjects: 36
Study 27053641 — intervention group
Group type: COMPARATOR
Intervention: Sham PES
Number of subjects: 36
Study 24710336 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily)
Number of subjects: 548
Study 24710336 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8-12 mg once daily)
Number of subjects: 548
Study 21684040 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 minutes, 1 mA)
Number of subjects: 20
Study 21684040 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 20550489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved topical levofloxacin (0.01% benzododecinium bromide)
Number of subjects: 62
Study 20550489 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved topical levofloxacin
Number of subjects: 62
Study 17502775 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole monotherapy (30 mg once daily) for 14 days
Number of subjects: 9
Study 17502775 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of carbamazepine with aripiprazole
Number of subjects: 9
Study 15994985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of randomized controlled trials (RCTs)
Number of subjects: 155
Study 15994985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of controlled clinical trials (CCTs)
Number of subjects: 155